Alphagan (brimonidine)
Company: Allergan
Approval Status: Approved September 1996
Treatment for: open-angle glaucoma and ocular hypertension
Areas: Ophthalmology
| General Information | Mechanism of Action | Additional Information |
General Information
Alphagan has been approved for the treatment of open-angle glaucoma and ocular hypertension.
Mechanism of Action
Alphagan is a selective alpha-2 agonist, which significantly lowers intraocular pressure with minimal effects on cardiovascular and pulmonary parameters. Its unique dual mechanism of action lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.
Additional Information
Glaucoma, an eye disease commonly characterized by excessive intraocular pressure, is a leading cause of blindness in the world.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
Medical Dictionary Searches
